Who Paid My Doc
Vicki Lyons
Allergy Ogden, UT Medical Doctor
NPI 1326013574 CMS profile 628617
4403 Harrison Blvd, Suite 4640, Ogden, UT 84403
General payments
$3,261
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Vicki Lyons of Ogden, UT is reported in the CMS Open Payments database as having received $3,261 across 155 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 53rd percentile of Allergy profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $450 | 15 | |
| 2024 | General | $499 | 22 | |
| 2023 | General | $246 | 13 | |
| 2022 | General | $666 | 40 | |
| 2021 | General | $437 | 19 | |
| 2020 | General | $650 | 32 | |
| 2019 | General | $314 | 14 |
Beside peers
- Vicki Lyons
- Allergy median
- Middle half of Allergy
- National median
In program year 2025, general payments to Vicki Lyons were reported at $450. Among 526 Allergy profiles paid that year, the median was $1,143 and the middle half received between $226 and $2,504.
Show as a table
| Year | Vicki Lyons | Allergy median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $314 | $506 | $151–$1,337 | $163 |
| 2020 | $650 | $409 | $108–$1,162 | $114 |
| 2021 | $437 | $549 | $125–$1,485 | $132 |
| 2022 | $666 | $666 | $161–$1,594 | $149 |
| 2023 | $246 | $780 | $186–$1,916 | $160 |
| 2024 | $499 | $1,031 | $271–$2,196 | $164 |
| 2025 | $450 | $1,143 | $226–$2,504 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 23 billing codesPaid by Medicare
$79,578
Medicare patients
181
Services billed
6,800
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 66% | |
| Arthritis | 52% | |
| Diabetes | 28% | |
| Depression | 27% | |
| Osteoporosis | 23% | |
| Ischemic heart disease | 19% | |
| Chronic kidney disease | 19% | |
| COPD | 17% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
First 5 of 10 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| DUPIXENT |
|
$161 | — | — |
| Xembify |
|
$125 | — | — |
| FASENRA |
|
$69 | — | — |
| TEZSPIRE |
|
$31 | — | — |
| Xhance |
|
$27 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See all 10 in the dashboard with a free accountRecords
155 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Allergy in Utah
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.